HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lars A Akslen Selected Research

Keratin-5 (Keratin 5)

12/2007Frequency of the basal-like phenotype in African breast cancer.
3/2006Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
2/2006Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
6/2005Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
5/2005A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.
8/2004Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
2/2004The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
10/2003Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Lars A Akslen Research Topics

Disease

71Neoplasms (Cancer)
11/2015 - 01/2002
30Endometrial Neoplasms (Endometrial Cancer)
11/2015 - 01/2002
23Breast Neoplasms (Breast Cancer)
11/2015 - 02/2004
15Melanoma (Melanoma, Malignant)
03/2014 - 12/2002
15Neoplasm Metastasis (Metastasis)
03/2014 - 10/2002
11Carcinoma (Carcinomatosis)
08/2015 - 08/2002
11Prostatic Neoplasms (Prostate Cancer)
04/2015 - 12/2002
4Anoxia (Hypoxia)
11/2015 - 01/2008
4Necrosis
11/2015 - 01/2008
4Aneuploidy (Aneuploid)
05/2011 - 02/2008
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2014 - 06/2008
3Nevus (Nevi)
03/2014 - 12/2005
3Disease Progression
01/2014 - 06/2009
3Ovarian Neoplasms (Ovarian Cancer)
09/2009 - 11/2003
3Microsatellite Instability
03/2006 - 01/2002
2Liposarcoma
05/2014 - 05/2006
2Hyperplasia
08/2013 - 06/2009
1Inflammation
11/2015
1Paraganglioma (Paragangliomas)
04/2015
1Adenocarcinoma
11/2013
1Adenoma (Adenomas)
08/2013
1Hypertension (High Blood Pressure)
01/2012

Drug/Important Bio-Agent (IBA)

12Cadherins (E-Cadherin)IBA
08/2015 - 04/2004
11Estrogens (Estrogen)FDA Link
11/2015 - 10/2003
10Biological Markers (Surrogate Marker)IBA
11/2013 - 10/2002
9Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2013 - 01/2003
8Keratin-5 (Keratin 5)IBA
12/2007 - 10/2003
7DNA (Deoxyribonucleic Acid)IBA
11/2015 - 10/2002
7Messenger RNA (mRNA)IBA
01/2014 - 08/2002
7HormonesIBA
01/2014 - 10/2002
6Phenobarbital (Luminal)FDA Link
11/2015 - 08/2004
6Phosphotransferases (Kinase)IBA
08/2015 - 06/2008
5ParaffinIBA
08/2015 - 04/2004
5Epidermal Growth Factor Receptor (EGF Receptor)IBA
05/2010 - 02/2008
4Doxorubicin (Adriamycin)FDA LinkGeneric
10/2015 - 11/2006
4Keratins (Keratin)IBA
04/2015 - 08/2004
4StathminIBA
01/2014 - 10/2010
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2012 - 06/2008
4Factor VIII (Coagulation Factor VIII)IBA
06/2012 - 11/2003
4Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
05/2012 - 01/2003
4Factor IX (PTC)FDA LinkGeneric
11/2011 - 08/2002
4Progesterone Receptors (Progesterone Receptor)IBA
09/2009 - 12/2007
4Proteins (Proteins, Gene)IBA
04/2009 - 01/2005
4AntibodiesIBA
05/2008 - 08/2004
3Complementary DNA (cDNA)IBA
01/2014 - 08/2002
3bevacizumabFDA Link
11/2013 - 01/2012
3Biological Tumor Markers (Tumor Markers)IBA
05/2011 - 04/2002
3beta CateninIBA
03/2006 - 04/2004
3N-methylsuccinimideIBA
03/2006 - 01/2002
2Fluorouracil (Carac)FDA LinkGeneric
10/2015 - 11/2006
2Mitomycin (Mitomycin-C)FDA LinkGeneric
10/2015 - 11/2006
2tyrosine receptor (receptor, tyrosine)IBA
08/2015 - 01/2010
2nestin (nestin protein)IBA
03/2014 - 06/2009
2Transcription Factors (Transcription Factor)IBA
01/2014 - 08/2009
2Thrombospondin 1IBA
05/2013 - 07/2009
2glucuronyl glucosamine glycan sulfate (Vessel)IBA
05/2012 - 01/2006
2Estrogen Receptor alphaIBA
09/2009 - 11/2008
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2009 - 01/2003
2OsteopontinIBA
01/2008 - 02/2006
2Cell Adhesion MoleculesIBA
01/2008 - 12/2007
2Angiogenesis InhibitorsIBA
05/2006 - 08/2004
2Vascular Endothelial Growth Factor CIBA
03/2006 - 01/2003
2Prostate-Specific Antigen (Semenogelase)IBA
01/2006 - 01/2006
2Codon (Codons)IBA
09/2005 - 08/2005
2Cyclin EIBA
06/2005 - 02/2004
2Cyclin D1IBA
12/2004 - 02/2004
2PTEN Phosphohydrolase (PTEN Phosphatase)IBA
12/2004 - 04/2002
2guanosine 5'-monophosphorothioateIBA
01/2003 - 12/2002
1NF-kappa B (NF-kB)IBA
11/2015
1von Willebrand FactorIBA
11/2015
1AnthracyclinesIBA
10/2015
1SynaptophysinIBA
04/2015
1Calcitonin (Calcitonin, Eel)FDA LinkGeneric
04/2015
1Neuropilin-1IBA
07/2014
1HLA-B Antigens (HLA-B)IBA
02/2014
1Sirolimus (Rapamycin)FDA Link
02/2014
1temsirolimusFDA Link
02/2014
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
02/2014
1Carbon MonoxideIBA
02/2014
1ridaforolimusIBA
02/2014
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2014
1G-Protein-Coupled Receptor Kinase 3IBA
01/2014
1Plasminogen Activators (Plasminogen Activator)IBA
01/2014
1taxaneIBA
01/2014
1Histone Deacetylase InhibitorsIBA
01/2014
1Paclitaxel (Taxol)FDA LinkGeneric
01/2014
1AldosteroneIBA
08/2013
1Interleukin-6 (Interleukin 6)IBA
01/2013
1HSP27 Heat-Shock ProteinsIBA
05/2012
1Estradiol (Estrace)FDA LinkGeneric
05/2012
1Hematoxylin (Haematoxylon)IBA
04/2012
1Eosine Yellowish-(YS) (Eosin)IBA
04/2012

Therapy/Procedure

7Heterologous Transplantation (Xenotransplantation)
05/2014 - 05/2009
7Drug Therapy (Chemotherapy)
01/2014 - 11/2006
4Prostatectomy (Retropubic Prostatectomy)
04/2015 - 04/2003
4Curettage
11/2013 - 10/2006
3Hysterectomy
05/2011 - 02/2008
1Transplants (Transplant)
05/2013
1Adjuvant Chemotherapy
02/2013
1Aftercare (After-Treatment)
08/2012